araag2/HINT huggingface dataset:
Clinical trial NCT02973399 (phase 1, status: terminated)
Conditions: cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: snx-5422 plus ibrutinib
SMILES: NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1
Reason stopped: 
    low recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Males or non-pregnant, non-breastfeeding females 18 years-of-age or older

          -  A diagnosis of CLL as defined by IWCLL 2008 criteria and currently on treatment with
             ibrutinib for at least 18 months with residual disease and without evidence of disease
             progression.

          -  No more than 4 prior lines of anti leukemia therapy (not including ibrutinib)

          -  Life expectancy of at least 9 months

          -  Karnofsky performance score 70

          -  Adequate baseline laboratory assessments

          -  Signed informed consent form

          -  Recovered from toxicities of previous anticancer therapy to CTCAE Grade ≤ 1

          -  Subjects with reproductive capability must agree to practice adequate contraception
             methods.

        Exclusion Criteria:

          -  Subjects experiencing toxicity with ibrutinib

          -  Prior treatment with any Hsp90 inhibitor.

          -  Major surgery or significant traumatic injury within 4 weeks of starting study
             treatment.

          -  Conventional chemotherapy or radiation within 4 weeks.

          -  The need for treatment with medications with clinically-relevant metabolism by the
             cytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or after administration of
             SNX-5422

          -  Screening ECG QTc interval 470 msec for females, 450 msec for males.

          -  At increased risk for developing prolonged QT interval unless corrected to within
             normal limits prior to first dose of SNX-5422

          -  Patients with chronic diarrhea or with Grade 2 or greater diarrhea despite appropriate
             medical management.

          -  Gastrointestinal diseases or conditions that could affect drug absorption or could
             alter the assessment of safety

          -  History of documented adrenal dysfunction not due to malignancy.

          -  History of chronic liver disease.

          -  Active hepatitis A or B.

          -  Current alcohol dependence or drug abuse.

          -  Use of an investigational treatment (except for ibrutinib) from 30 days prior to the
             first dose

          -  Glaucoma, retinitis pigmentosa, macular degeneration, or any retinal changes detected
             by ophthalmological examination that are considered clinically important by examiner.

          -  Psychological or social reasons that would hinder or prevent compliance with the
             requirements of the protocol or compromise the informed consent process.
Clinical trial NCT02975557 (phase 1/phase 2, status: terminated)
Conditions: dry eye, ocular graft vs host disease, meibomian gland dysfunction
ICD codes: H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121, H02.881, H02.882, H02.884, H02.885, H02.883, H02.886, H02.889
Drugs: brimonidine 0.15%, brimonidine 0.075%, placebo
SMILES: BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12, BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    slow accrual of subjects. may take longer than expected to complete the trial.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Aged 18 years or older.

          2. Capable of giving informed consent and does provide informed consent.

          3. Diagnosis of Meibomian Gland Disease

          4. Women must be post-menopausal ≥ 1 year, or surgically sterilized. If not, a negative
             urine pregnancy test is required within 7 days of the participant receiving first dose
             of study drug along with definite evidence of contraceptive use during the duration of
             the study. Women of reproductive age should use a method of birth control that is
             acceptable to the participant and the study doctor. This may include oral
             contraceptive pills, birth control implants, barrier methods or abstinence. If a
             participant suspects pregnancy after being enrolled, another pregnancy test will be
             administered. If the test is positive, the participant will be discontinued from the
             study immediately.

        Exclusion Criteria:

          1. Allergic to Brimonidine or any similar products, or excipients of Brimonidine

          2. Currently receiving any Brimonidine preparation as a part of glaucoma management

          3. Receiving or have received within 30 days any experimental systemic medication.

          4. Active ocular infection or ocular allergies.

          5. Any history of eyelid surgery or ocular surgery within the past 3 months.

          6. Corneal epithelial defect larger than 1 mm2 in either eye.

          7. Have active drug/alcohol dependence or abuse history.

          8. Vulnerable populations, such as neonates, pregnant women, children, prisoners,
             institutionalized individuals, or others who may be considered vulnerable populations.
Clinical trial NCT02993471 (phase 1, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: drug cocktail, ixekizumab
SMILES: CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females with chronic moderate or severe plaque psoriasis for at least 6
             months who are candidates for systemic therapy or phototherapy

          -  Men and women of childbearing potential must agree to use a reliable method of birth
             control and men may not donate sperm for the duration of the study. Women must test
             negative for pregnancy at screening and agree not to become pregnant during the study
             and until the first normal period following the end of the study

          -  Have a body mass index (BMI) of 18.5 to 40.0 kilograms per square meter (kg/m²),
             inclusive, at screening

          -  Have greater than or equal to (≥) 10 percent body surface area (BSA) involvement at
             screening and first admission to the clinical research unit (CRU)

          -  Have both a Static Physicians Global Assessment (sPGA) score of ≥3 and Psoriasis Area
             Severity Index (PASI) score ≥12 at screening and first admission to the CRU

        Exclusion Criteria:

          -  Forms of psoriasis other than chronic plaque-type

          -  Pregnant or nursing (lactating women)

          -  History of an ongoing, chronic or recurrent infectious disease, or evidence of
             tuberculosis infection

          -  Have major surgery within 8 weeks prior to first admission to the clinical research
             unit or during the study

          -  Have a history of lymphoproliferative disease, or signs or symptoms of
             lymphoproliferative disease, or have active or history of malignant disease, or have
             uncontrolled cerebrocardiovascular or neuropsychiatric disease

          -  Require treatment with the cocktail drugs or with inhibitors of cytochrome P450 (CYP)
             3A, CYP2C9, CYP2D6, CYP2C19, CYP1A2, or with inducers of CYP3A or CYP1A2, or with
             rifampin (inducer of multiple CYPs) or with substrates of CYP3A, CYP2C9, CYP2D6,
             CYP2C19, or CYP1A2 with narrow therapeutic indices within 14 days prior to the first
             administration of the drug cocktail through the end of Week 12 assessments

          -  Have any known allergy or hypersensitivity to any component of the study cocktail or
             ixekizumab

          -  Have participated in any other study with ixekizumab, secukinumab or brodalumab, or
             have been prescribed ixekizumab or secukinumab
Clinical trial NCT03014219 (phase 1, status: withdrawn)
Conditions: perianal fistula
ICD codes: K64.5, A60.1
Drugs: only 1 arm: treatment with msc-afp
SMILES: COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1
Reason stopped: 
    fda approval was not obtained until adult trial completes accrual
  
Eligibility criteria:

        Inclusion Criteria

          1. Males and females 12-17 years of age.

          2. Residents of the United States.

          3. Crohn's disease with single or multiple draining complex perianal fistulae (definition
             as below) for at least three months despite standard therapy (definition below).

          4. Concurrent therapies with corticosteroids, 5-ASA drugs, thiopurines, MTX, antibiotics,
             and anti-TNF therapy are permitted.

          5. All patients should have undergone a colonoscopy in last 12 months to rule out
             malignant or premalignant condition

          6. Have no contraindications to MR evaluations: e.g. pacemaker or magnetically active
             metal fragments, claustrophobia

          7. Ability to comply with protocol

          8. Competent and able to provide written informed consent (and assent where appropriate).

          9. Must have failed standard medical therapy including anti-TNF agents

        Exclusion Criteria

          1. Inability to obtain informed consent (and assent where appropriate).

          2. Clinically significant medical conditions within the six months before administration
             of MSCs: e.g. sepsis, pneumonia active serious infection or other conditions that
             would, in the opinion of the investigators, compromise the safety of the patient.

          3. Specific exclusions;

             a. Evidence of hepatitis B, C, or HIV

          4. History of cancer including melanoma (with the exception of localized skin cancers)

          5. Investigational drug within thirty (30) days of baseline

          6. A resident outside the United States

          7. Pregnant or trying to become pregnant, or breast feeding.

          8. History of clinically significant auto-immunity (other than Crohn's disease) or any
             previous example of fat-directed autoimmunity

          9. Previous allergic reaction to a perianal fistula plug.

         10. If adipose tissue is not technically feasible

         11. Weight less than 35 kg

         12. Allergic to local anesthetics

         13. Non-enterocutaneous tracts (i.e. recto-vaginal, entero-vesicular)
Clinical trial NCT03025009 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: ly3192767, basal insulin peglispro, insulin glargine, placebo
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Are overtly healthy males or females, as determined by medical history and physical
             examination

          -  Have a body mass index (BMI) of >18.5 and <30.0 kilogram per square meter (kg/m²),
             inclusive

        Exclusion Criteria:

          -  Are currently enrolled in a clinical trial involving an investigational product or any
             other type of medical research judged not to be scientifically or medically compatible
             with this study

          -  Have participated, within the last 30 days, in a clinical trial involving an
             investigational product. If the previous investigational product has a long half-life,
             3 months or 5 half-lives (whichever is longer) should have passed

          -  Have participated as a participant in a first-in-human study within 90 days of the
             initial dose of study drug

          -  Have known allergies to insulin, heparin, or related drugs, or history of relevant
             allergic reactions of any origin

          -  Have a history or presence of cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, chronic inflammatory disease, or
             neurological disorders capable of significantly altering the absorption, metabolism,
             or elimination of drugs; of constituting a risk when taking the study medication; or
             of interfering with the interpretation of data
Clinical trial NCT03026166 (phase 1/phase 2, status: terminated)
Conditions: small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: ipilimumab, nivolumab, rovalpituzumab tesirine
SMILES: COC1=CC=CC=C1OCC(O)CO, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    enrollment was stopped after the dose-limiting toxicity (dlt) evaluation phase of cohort 2.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Participants with histologically or cytologically confirmed extensive-stage small cell
             lung cancer (SCLC) with progressive disease after at least one platinum-based
             chemotherapeutic regimen and with evaluable or measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate hematologic, hepatic, and renal function

        Exclusion Criteria:

          -  Has active, known, or suspected autoimmune disease

          -  Had prior exposure to an immuno-oncology or pyrrolobenzodiazepine (PBD)-based drug
Clinical trial NCT03031691 (phase 1, status: completed)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: brontictuzumab, trifluridine/tipiracil
SMILES: ClC1=C(CN2CCCC2=N)NC(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed metastatic colorectal cancer (mCRC) previously treated with
             fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF
             biological therapy, and if KRAS wild-type, an anti-EGFR therapy

          -  ECOG performance status 0 or 1

        Exclusion Criteria:

          -  Prior treatment with gamma secretase inhibitors or other Notch 1 inhibitors

          -  Subjects with known active HIV infection. Subjects with HIV that are under a stable
             anti-retroviral regimen and have no evidence of immune deficiency (normal CD4 counts),
             undetectable viral load, and no HIV-related infections are eligible

          -  Subjects with uncontrolled diarrhea <30 days prior to first administration of study
             drug

          -  Subjects with any history of or current clinically significant gastrointestinal
             disease including, but not limited to:

               -  Inflammatory bowel disease (including ulcerative colitis and Crohn's disease)

               -  Active peptic ulcer disease

               -  Known intraluminal metastatic lesion(s) with risk of bleeding
Clinical trial NCT03047096 (phase 1, status: unknown status)
Conditions: osteoarthritis, pain syndrome, intra-articular injection
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: hyaluronic acid, hyaluronic acid and corticosteroids
SMILES: CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O, CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

        According to radiographic findings, patients who are suffering from knee OA for over 3
        months have to be stage II-IV according to the Kellgren-Lawrence (KL) grade by a senior
        radiologist. The diagnosis of symptomatic knee OA is based on American Rheumatism
        Association classification criteria for knee osteoarthritis.

        Exclusion Criteria:

        Exclusion criteria are the diagnosis of rheumatoid arthritis or other inflammatory OA,
        presence of trauma or pain-causing diseases, treatment with oral medications in recent 3
        days, physiotherapy and intra-articular injection of HA or CS in the past 6 months.
        Participants who are allergic to any of the medications used in this study or diagnosed
        with current systemic infection are also excluded.
Clinical trial NCT03051646 (early phase 1, status: completed)
Conditions: fatigue, overheating
ICD codes: R53.83, G93.3, R53.82, R53.0, T67.6XXS, T67.6XXA, T67.6XXD
Drugs: acetylsalicylic acid at 1st visit, then placebo at 2nd visit, placebo at 1st visit, then acetylsalicylic acid at 2nd visit
SMILES: CC(=O)OC1=CC=CC=C1C(O)=O, CC(=O)OC1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  RRMS

          -  self report of overheating during exercise

          -  low physical disability (EDSS total score 4.5 or less); fully ambulatory without aid

          -  exacerbation-free (and no use of corticosteroids) for 6 weeks prior

          -  BMI 35 or lower

        Exclusion Criteria:

          -  uncontrolled hypertension or vascular disease of the legs

          -  current medications for heart or blood pressure problem

          -  prior history of head injury, stroke, or other neurological disease/disorder

          -  currently taking antipyretics or pain medication daily

          -  presence of major depressive disorder or other psychiatric diagnosis

          -  formally diagnosed sleep disorder

          -  pulmonary disease, heart disease or other heart problem

          -  diabetes mellitus or problem with blood sugar levels

          -  lower body weakness or reliance on supportive devices for walking (as indicated
             through EDSS)

          -  counter indications to aspirin use: history of confirmed peptic ulcer,
             gastrointestinal or sever gynecological bleeding; tarry stool or fecal occult blood;
             syndrome of asthma, rhinitis or nasal polyps
Clinical trial NCT03054207 (phase 1, status: terminated)
Conditions: hiv
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: clopidogrel 300mg tablet, prasugrel 60mg
SMILES: [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl, CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1
Reason stopped: 
    difficulty to recruit
  
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy males >18 years

          -  Understanding of French language and able to give an inform consent

          -  Anti-HIV therapy with ritonavir or cobicistat (for HIV group)

          -  Stable antiretroviral treatment since at least 2 weeks (for HIV group)

          -  Viremia <100 copies/ml (for HIV group)

        Exclusion Criteria:

          -  renal failure: calculated creatinine Clearance (cockcroft) < 50ml/min

          -  hepatic impairment (ASAT, ALAT, bilirubin, gamma-GT more than 2-fold increase)

          -  smoker >1 pack/day

          -  hypersensitivity to any of the drugs used

          -  intake of any drug or particular food (grapefruit) that can affect CYP activities
             inhibitors (in the last 10 days before the start of the study or 4 half-life after the
             last intake)

          -  pathologies or drugs associated with an increased bleeding risk such as aspirin,
             non-steroidal anti-inflammatory drugs, steroids and serotonin reuptake inhibitors (in
             the last 10 days before the start of the study or 4 half-life after the last intake)

          -  bleeding familial history or antecedent or haemorrhagic disease
Clinical trial NCT03055845 (phase 1, status: completed)
Conditions: low back pain
ICD codes: M54.50, M54.51, M54.59
Drugs: sta363, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent prior to any study-related procedures

          -  Chronic discogenic low back pain present for more than 6 months prior to the screening
             visit

          -  20 to 60 years of age at the screening visit

          -  Insufficient response to at least 6 months of non-operative treatment (analgesics
             and/or antiinflammatory medication, physiotherapy etc.)

          -  A single lumbar disc appropriate for treatment at L3/4 to L5/S1, based on clinical
             evaluation by the investigator

          -  Pfirrmann grade II-III

          -  Ability to understand the written and verbal information about the study

        Exclusion Criteria:

          -  Treatment with any investigational product within 3 months prior to the screening
             visit

          -  More than one painful intervertebral disc

          -  A painful intervertebral disc above L3/4 level

          -  Current infection or prior history of spinal infection (e.g., discitis, septic
             arthritis, epidural abscess) or an active systemic infection

          -  Previous lumbar spine surgery

          -  Previous disc invasive treatment procedures at the affected level(s) (e.g.,
             intradiscal electrothermal therapy, intradiscal radiofrequency thermocoagulation)

          -  Pfirrmann grade I, IV and V

          -  Evidence of prior lumbar vertebral body fracture or trauma

          -  Need for spinal decompression assessed by the investigator

          -  Presence of disc extrusion or sequestration

          -  Patients previously included in the study

          -  Patients suffering from psychosomatic pain in the opinion of the investigator

          -  Referred leg pain of compressive origin

          -  Known alcohol and/or drug abuse

          -  Severe intercurrent illness (e.g. rheumatic disease or chronic pain syndrome) or
             concomitant treatment (e.g. immunosuppressive drugs), which, in the opinion of the
             investigator, may put the patient at risk when participating in the study, or affect
             the patient's ability to take part in the study

          -  Clinically significant abnormalities in clinical chemistry or haematology parameters
             as assessed by the investigator

          -  Pregnant or lactating females or intention to become pregnant within the study period

          -  Known allergy to any of the components of the drug product or placebo

          -  Known opioid allergy or intolerance

          -  Patients requiring treatment with warfarin or other anticoagulant therapy

          -  Unwillingness to refrain from treatment with non-steroidal anti-inflammatory drugs
             (NSAIDs) within 5 days before the planned study treatment

          -  Body weight less than 50 kg